| Titolo |
Pubblicato in |
Anno |
| Sarcopenia in Breast Cancer Patients: A Systematic Review and Meta-Analysis |
CANCERS |
2024 |
| Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey |
JOURNAL OF GYNECOLOGIC ONCOLOGY |
2024 |
| Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer |
ARCHIVES OF GYNECOLOGY AND OBSTETRICS |
2024 |
| Advances in small molecule maintenance therapies for high-grade serous ovarian cancer |
EXPERT OPINION ON PHARMACOTHERAPY |
2023 |
| Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives |
HEALTHCARE |
2023 |
| Magnetic resonance imaging-radiomics in endometrial cancer: a systematic review and meta-analysis |
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2023 |
| Sexual dysfunctions in breast cancer patients: evidence in context |
SEXUAL MEDICINE REVIEWS |
2023 |
| Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions |
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2023 |
| The Efficacy of Dienogest in Reducing Disease and Pain Recurrence After Endometriosis Surgery: a Systematic Review and Meta-Analysis |
REPRODUCTIVE SCIENCES |
2023 |
| Therapeutic Approaches to Vulvar Cancer: A Review of Literature |
CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY |
2023 |
| Imaging of Peritoneal Carcinomatosis in Advanced Ovarian Cancer: CT, MRI, Radiomic Features and Resectability Criteria |
CANCERS |
2023 |
| Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study |
FRONTIERS IN ONCOLOGY |
2023 |
| Pfizer-BioNtech COVID-19 vaccine in gynecologic oncology patients: a prospective cohort study |
VACCINES |
2022 |
| CT-based radiomics and deep learning for BRCA mutation and progression-free survival prediction in ovarian cancer using a multicentric dataset |
CANCERS |
2022 |
| Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer |
GYNECOLOGIC ONCOLOGY |
2022 |
| Age-Adjusted Charlson Comorbidity Index Predicts Survival in Endometrial Cancer Patients |
GYNECOLOGIC AND OBSTETRIC INVESTIGATION |
2022 |
| Systematic lymph node dissection during interval debulking surgery for advanced epithelial ovarian cancer: a systematic review and meta-analysis |
JOURNAL OF GYNECOLOGIC ONCOLOGY |
2022 |
| An update on current pharmacotherapy for vulvar cancer |
EXPERT OPINION ON PHARMACOTHERAPY |
2022 |
| MRI- and Histologic-Molecular-Based Radio-Genomics Nomogram for Preoperative Assessment of Risk Classes in Endometrial Cancer |
CANCERS |
2022 |
| Role of circulating biomarkers in platinum-resistant ovarian cancer |
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
2021 |
